Morgan Stanley analyst Terence Flynn lowered the firm’s price target on United Therapeutics to $316 from $320 and keeps an Overweight rating on the shares after adjusting the firm’s models for recent IQVIA trends as well as intraquarter updates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on UTHR: